查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1829859

2025年子宮頸癌診斷全球市場報告

Cervical Cancer Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，子宮頸癌診斷市場規模強勁成長，從2024年的92.7億美元增加至2025年的97.6億美元，複合年成長率為5.3%。預測期內的成長可歸因於認知度的提高、篩檢計畫的推進、HPV疫苗接種、技術進步以及人口老化。

子宮頸癌診斷市場預計將在未來幾年強勁成長，到2029年將達到122.9億美元，複合年成長率為5.9%。預測期內的成長歸因於HPV相關癌症的增加、新興市場、分子檢測、遠端醫療和遠距篩檢的進步。預測期內的主要趨勢包括HPV檢測、液基細胞學、自動化和數位病理學以及篩檢和治療方案。

子宮頸癌是一種發生於子宮頸（子宮下部）的鱗狀細胞癌。子宮頸癌診斷設備用於檢測影響子宮頸的癌症。

子宮頸癌診斷的主要類型包括乳頭抹片檢查、HPV檢測、陰道鏡檢查、切片檢查、子宮頸管刮除術和其他診斷方法。乳頭抹片檢查是一種用於檢測女性子宮頸癌的方法。此診斷過程涵蓋21歲以下、21至29歲、30至65歲以及65歲以上的年齡層。這些檢測的最終用戶包括醫院、專科診所、癌症和放射治療中心以及診斷中心等。

2025年春季美國關稅的突然上調及其引發的貿易摩擦對醫療設備行業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰使情況更加複雜，因為由於關稅而更換供應商通常需要重新認證醫療設備，導致市場進入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供子宮頸癌診斷市場統計數據，包括全球子宮頸癌診斷行業市場規模、區域佔有率、子宮頸癌診斷市場佔有率競爭對手、詳細的子宮頸癌診斷細分市場、市場趨勢和商業機會，以及您在子宮頸癌診斷行業取得成功所需的數據。本子宮頸癌診斷市場研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供所需的全方位觀點。

我們預測未來五年該市場將成長5.9%，較我們先前對該市場的預測略有下降0.2%。下降主要源自於美國與其他國家之間關稅的影響。這可能會透過對來自義大利和韓國等主要地區的液基乳頭瘤病毒 (HPV)去氧核糖核酸(DNA)雜合反應探針徵收套件直接影響美國，從而可能降低篩檢能力並增加早期癌症檢測的成本。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響，這種影響可能會更加廣泛。

子宮頸癌診斷檢測在早期發現的應用日益廣泛，預計將推動子宮頸癌診斷市場的成長。女性對子宮頸癌認知的不斷提高，以及全球癌症組織和各國政府對早期發現和預防檢測的日益重視，都促進了市場的擴張。例如，美國政府機構疾病管制與預防中心 (CDC) 在 2024 年 7 月報告稱，2021 年美國新增子宮頸癌病例 12,536 例，2022 年有 4,051 名女性死於子宮頸癌。子宮頸癌診斷檢測的廣泛應用和對早期發現的重視是推動子宮頸癌診斷市場成長的關鍵因素。

子宮頸癌盛行率的上升預計將成為子宮頸癌診斷市場成長的主要驅動力。子宮頸癌發生在子宮頸（子宮下部較窄的部分），是一個嚴重的健康問題。子宮頸癌診斷檢測在早期發現、準確診斷和有效治療中發揮著至關重要的作用。例如，根據美國臨床腫瘤學會 (ASCO) 患者資訊網站 Cancer.net 的估計，美國約有 13,960 名女性將被診斷出患有侵襲性子宮頸癌。因此，子宮頸癌發生率的上升預計將支持子宮頸癌診斷市場的成長。

為了提高篩檢的可近性並提高早期發現率，子宮頸癌診斷市場的主要企業正致力於開發技術先進的解決方案，例如HPV自採集。 HPV自採集可讓個人獨立採集檢體進行人類乳突病毒（HPV）檢測，HPV是子宮頸癌的主要原因。例如，2024年5月，瑞士製藥公司F. Hoffmann-La Roche AG的HPV自採集解決方案獲得FDA核准。這項技術創新標誌著子宮頸癌篩檢領域的一個重要里程碑，提高了篩檢的可近性，特別是對於服務不足的人。此解決方案可讓女性私下採集陰道樣本，並使用羅氏的cobas分子HPV檢測試劑盒進行檢測，這與世界衛生組織（WHO）在2030年消除子宮頸癌的目標一致。 FDA的核准是在IMPACT試驗成功完成之後進行的，該試驗檢驗了該解決方案在不同人群中的有效性。

子宮頸癌診斷行業的主要企業正在優先開發先進的數位診斷系統，以提高篩檢的可及性和早期發現率。數位診斷系統利用人工智慧 (AI) 和數位工具等最尖端科技來支援子宮頸癌的檢測、診斷和管理。例如，2024 年 2 月，美國醫療技術公司 Hologic 的 Genius 數位診斷系統獲得了 FDA 批准。這項突破性的解決方案將 Genius Cervical AI 演算法與先進的體積成像技術相結合，顯著提高了癌前病變和子宮頸癌細胞的檢測率。與傳統方法相比，它將假陰性減少了 28%，從而改善了早期發現和患者預後。透過數位化細胞學切片並利用人工智慧指導細胞學家和病理學家識別需要進一步分析的區域，它最佳化了工作流程效率並促進了醫療專業人員之間的遠端協作。

2022年2月，醫療設備和試劑製造商BD（Becton, Dickinson & Company）收購了Cytognos，收購金額未揭露。 BD收購Cytognos加強了對慢性病管理的承諾，並擴展了其診斷產品組合、免疫評估測試和資訊學，以深入了解免疫系統、免疫反應和微小殘留疾病（MRD）。 Cytognos總部位於西班牙，專門提供用於子宮頸癌診斷的臨床流式細胞技術解決方案。

子宮頸癌診斷市場的主要企業包括雅培實驗室 (Abbott Laboratories)、碧迪公司 (Becton Dickinson and Company, BD)、Bio-Rad Laboratories Inc.、F. Hoffmann-La Roche Ltd.、Hologic Inc.、QIAGEN NV、Quest Diagicotics Incorporated、西門子醫療股份公司 Ltd. Inc.、Guided Therapeutics Inc.、賽默飛世爾科技 (Thermo Fisher Scientific Inc.)、卡爾蔡司股份公司 (Carl Zeiss AG)、OncoHealth Corporation、Arbor Vita Corporation、Micromedic Technologies Ltd.、Trovagene Inc.、羅氏診斷 (Roche Diagnostics)、Nucleix Ltd.、華大基因 Ltd. Inc.、Invitae Corporation、Natera Inc.、NeoGenomics Laboratories Inc.、珀金埃爾默公司 (PerkinElmer Inc.)、Sysmex Corporation、Veracyte Inc. 和 Zymo Research Corporation。

2024年，北美是子宮頸癌診斷市場最大的地區。亞太地區是子宮頸癌診斷市場的第二大地區。子宮頸癌診斷市場報告涵蓋亞太地區、西歐、東歐、北美、南美以及中東和非洲。

子宮頸癌診斷市場報告涵蓋的國家包括澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國、美國、義大利、西班牙和加拿大

子宮頸癌診斷市場涵蓋用於診斷子宮頸癌的分析儀、試劑和其他產品的銷售。市場價值包括服務供應商銷售或包含在其服務產品中的相關商品的價值。僅包括企業之間交易或銷售給最終消費者的商品和服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球子宮頸癌診斷：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球子宮頸癌診斷市場：成長率分析
  • 全球子宮頸癌診斷市場表現：規模與成長，2019-2024
  • 全球子宮頸癌診斷市場預測：規模與成長，2024-2029年，2034年
  • 全球子宮頸癌診斷：總目標市場（TAM）

第6章 市場細分

  • 全球子宮頸癌診斷市場（按診斷測試、效能和預測），2019-2024 年、2024-2029 年、2034 年
  • 子宮頸抹片抹片檢查
  • HPV檢測
  • 陰道鏡檢查
  • 切片檢查和子宮頸刮除術
  • 其他診斷測試
  • 全球子宮頸癌診斷市場依年齡層、績效及預測（2019-2024 年、2024-2029 年、2034 年）
  • 未滿21歲
  • 21至29歲
  • 30至65歲
  • 65歲或以上
  • 全球子宮頸癌診斷市場（按最終用戶、績效和預測），2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 專科診所
  • 癌症及放射治療中心
  • 診斷中心
  • 全球子宮頸癌診斷市場：子宮頸抹片檢查細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 傳統子宮頸抹片抹片檢查
  • 液態子宮頸抹片
  • 全球子宮頸癌診斷市場：按 HPV 檢測類型、效能和預測細分，2019-2024 年、2024-2029 年、2034 年
  • 基於DNA的HPV檢測
  • 基於RNA的HPV檢測
  • 雜交捕獲HPV檢測
  • 其他 HPV 檢測
  • 全球子宮頸癌診斷市場：陰道鏡細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 標準陰道鏡檢查
  • 電子陰道鏡檢查
  • 光學陰道鏡檢查
  • 全球子宮頸癌診斷市場：切片檢查及子宮頸刮除細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 穿刺切片檢查
  • 子宮頸刮除術（ECC）
  • 切除術
  • 陰道鏡切片檢查
  • 全球子宮頸癌診斷市場：依其他診斷檢驗細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 使用醋酸進行目視檢查（VIA）
  • 子宮頸巴氏試驗
  • 血液檢查
  • 其他專業測試

第7章 區域和國家分析

  • 全球子宮頸癌診斷市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球子宮頸癌診斷市場：依國家、績效及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 子宮頸癌診斷市場：競爭格局
  • 子宮頸癌診斷市場：公司簡介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Becton Dickinson and Company（BD）Overview, Products and Services, Strategy and Financial Analysis
    • Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Zilico Ltd.
  • Guided Therapeutics Inc.
  • Thermo Fisher Scientific Inc.
  • Carl Zeiss AG
  • OncoHealth Corporation
  • Arbor Vita Corporation
  • Micromedic Technologies Ltd.
  • Trovagene Inc.
  • Roche Diagnostics
  • Nucleix Ltd.
  • BGI Genomics Co. Ltd.
  • Cepheid

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年子宮頸癌診斷市場：提供新機會的國家
  • 2029年子宮頸癌診斷市場：細分市場帶來新機會
  • 子宮頸癌診斷市場2029年：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r32448u

Cervical cancer is a form of squamous cell carcinoma that develops in the cervix, which is the lower part of the uterus. Diagnostic devices for cervical cancer are employed to detect cancer affecting the cervix.

The primary types of cervical cancer diagnostics include pap smear tests, HPV tests, colposcopy, biopsy, endocervical curettage, and other diagnostic procedures. A pap smear test is a method used for the detection of cervical cancer in women. This diagnostic process encompasses age groups such as those under 21, those aged 21 to 29, those aged 30 to 65, and those over 65. These diagnostics are utilized by various end-users, including hospitals, specialty clinics, cancer and radiation therapy centers, as well as diagnostic centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The cervical cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cervical cancer diagnostics market statistics, including cervical cancer diagnostics industry global market size, regional shares, competitors with a cervical cancer diagnostics market share, detailed cervical cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cervical cancer diagnostics industry. This cervical cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cervical cancer diagnostics market size has grown strongly in recent years. It will grow from $9.27 billion in 2024 to $9.76 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increased awareness and screening programs, hpv vaccination, technological advancements, aging population.

The cervical cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $12.29 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing hpv-related cancers, emerging markets, molecular testing advances, telemedicine and remote screening. Major trends in the forecast period include hpv testing, liquid-based cytology, automation and digital pathology, screen-and-treat programs.

The forecast of 5.9% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through tariffs on liquid-based cytology collection kits and human papillomavirus (HPV) deoxyribonucleic acid (DNA) hybridization probes, sourced from key regions such as Italy and South Korea, which could lead to reduced screening capacity and higher costs for early cancer detection.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing adoption of cervical cancer diagnostic tests for early detection is expected to drive the growth of the cervical cancer diagnostics market. Rising awareness among women about cervical cancer, along with global cancer organizations and governments' emphasis on early testing for detection and prevention, contributes to the market's expansion. For example, in July 2024, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported 12,536 new cases of cervical cancer in the United States in 2021, while in 2022, the disease led to 4,051 fatalities among women. The growing adoption of cervical cancer diagnostic tests and the focus on early diagnosis are key factors driving the growth of the cervical cancer diagnostics market.

The increasing prevalence of cervical cancer is anticipated to be a key driver of growth in the cervical cancer diagnostics market. Cervical cancer, originating in the cervix, the narrow lower portion of the uterus, is a serious health concern. Diagnostic tests for cervical cancer play a pivotal role in early detection, accurate diagnosis, and effective treatment. For instance, estimates from Cancer.net, the patient information website of the American Society of Clinical Oncology (ASCO), suggest that approximately 13,960 women in the United States will be diagnosed with invasive cervical cancer. Consequently, the rising incidence of cervical cancer is expected to underpin the growth of the cervical cancer diagnostics market.

Leading companies in the cervical cancer diagnostics market are emphasizing the development of technologically advanced solutions, such as HPV self-collection methods, to enhance screening accessibility and improve early detection rates. HPV self-collection solutions enable individuals to independently collect samples for testing the human papillomavirus (HPV), a primary cause of cervical cancer. For instance, in May 2024, F. Hoffmann-La Roche AG, a pharmaceutical company based in Switzerland, secured FDA approval for its HPV self-collection solution. This innovation marks a significant milestone in cervical cancer screening by improving accessibility, particularly for underserved populations. The solution allows women to privately collect vaginal samples for testing using Roche's Cobas molecular HPV test, aligning with the World Health Organization's objective of eradicating cervical cancer by 2030. The FDA approval follows the successful IMPACT trial, which validated the solution's effectiveness across various demographic groups.

Prominent players in the cervical cancer diagnostics industry are prioritizing the development of advanced digital diagnostic systems to enhance screening accessibility and early detection capabilities. Digital diagnostic systems leverage cutting-edge technologies, including artificial intelligence (AI) and digital tools, to support the detection, diagnosis, and management of cervical cancer. For example, in February 2024, Hologic, Inc., a US-based health technology firm, obtained FDA clearance for its Genius Digital Diagnostics System. This groundbreaking solution integrates the Genius Cervical AI algorithm with advanced volumetric imaging technology to significantly improve the detection of precancerous lesions and cervical cancer cells. By reducing false negatives by 28% compared to traditional methods, the system enhances early detection and patient outcomes. It digitizes cytology slides and employs AI to guide cytologists and pathologists in identifying areas needing further analysis, thereby optimizing workflow efficiency and facilitating remote collaboration among healthcare professionals.

In February 2022, BD (Becton, Dickinson, and Company), a manufacturer of medical devices and reagents, acquired Cytognos for an undisclosed amount. BD's acquisition of Cytognos strengthens its commitment to chronic disease management, expanding its diagnostic portfolio, immune assessment tests, and informatics to gain deeper insights into the immune system, immune response, and Minimal Residual Disease (MRD). Cytognos, a Spain-based company, specializes in providing clinical flow cytometry solutions used in cervical cancer diagnostics.

Major companies operating in the cervical cancer diagnostics market include Abbott Laboratories, Becton Dickinson and Company (BD), Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Zilico Ltd., Guided Therapeutics Inc., Thermo Fisher Scientific Inc., Carl Zeiss AG, OncoHealth Corporation, Arbor Vita Corporation, Micromedic Technologies Ltd., Trovagene Inc., Roche Diagnostics, Nucleix Ltd., BGI Genomics Co. Ltd., Cepheid, Exact Sciences Corporation, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., PerkinElmer Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation

North America was the largest region in the cervical cancer diagnostics market in 2024 Asia-Pacific was the second largest region in the cervical cancer diagnostics market. The regions covered in the cervical cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cervical cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The cervical cancer diagnostics market consists of sales of analyzer, reagents, and others that are used for the diagnosis of cervical cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cervical Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cervical cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cervical cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cervical cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Diagnostic Test: Pap Smear Test; HPV Test; Colposcopy; Biopsy and Endocervical Curettage; Other Diagnostic Tests
  • 2) By Age Group: Below 21; Age between 21 to 29; Age between 30 to 65; Above 65
  • 3) By End User: Hospitals; Specialty Clinics; Cancer And Radiation Therapy Centers; Diagnostic Centers
  • Subsegments:
  • 1) By Pap Smear Test: Conventional Pap Smear; Liquid-Based Pap Smear
  • 2) By HPV Test: DNA-Based HPV Test; RNA-Based HPV Test; Hybrid Capture HPV Test; Other HPV Tests
  • 3) By Colposcopy: Standard Colposcopy; Digital Colposcopy; Optical Colposcopy
  • 4) By Biopsy And Endocervical Curettage: Punch Biopsy; Endocervical Curettage (ECC); Cone Biopsy; Colposcopic Biopsy
  • 5) By Other Diagnostic Tests: Visual Inspection With Acetic Acid (VIA); Cervical Cytology Testing; Blood Tests; Other Specialty Tests
  • Companies Mentioned: Abbott Laboratories; Becton Dickinson and Company (BD); Bio-Rad Laboratories Inc.; F. Hoffmann-La Roche Ltd.; Hologic Inc.; QIAGEN N.V.; Quest Diagnostics Incorporated; Siemens Healthineers AG; Zilico Ltd.; Guided Therapeutics Inc.; Thermo Fisher Scientific Inc.; Carl Zeiss AG; OncoHealth Corporation; Arbor Vita Corporation; Micromedic Technologies Ltd.; Trovagene Inc.; Roche Diagnostics; Nucleix Ltd.; BGI Genomics Co. Ltd.; Cepheid; Exact Sciences Corporation; Guardant Health Inc.; Invitae Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; PerkinElmer Inc.; Sysmex Corporation; Veracyte Inc.; Zymo Research Corporation
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cervical Cancer Diagnostics Market Characteristics

3. Cervical Cancer Diagnostics Market Trends And Strategies

4. Cervical Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Cervical Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Cervical Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Cervical Cancer Diagnostics Market Growth Rate Analysis
  • 5.4. Global Cervical Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Cervical Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Cervical Cancer Diagnostics Total Addressable Market (TAM)

6. Cervical Cancer Diagnostics Market Segmentation

  • 6.1. Global Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pap Smear Test
  • HPV Test
  • Colposcopy
  • Biopsy and Endocervical Curettage
  • Other Diagnostic Tests
  • 6.2. Global Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Below 21
  • Age between 21 to 29
  • Age between 30 to 65
  • Above 65
  • 6.3. Global Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Cancer and Radiation Therapy Centers
  • Diagnostic Centers
  • 6.4. Global Cervical Cancer Diagnostics Market, Sub-Segmentation Of Pap Smear Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Conventional Pap Smear
  • Liquid-Based Pap Smear
  • 6.5. Global Cervical Cancer Diagnostics Market, Sub-Segmentation Of HPV Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • DNA-Based HPV Test
  • RNA-Based HPV Test
  • Hybrid Capture HPV Test
  • Other HPV Tests
  • 6.6. Global Cervical Cancer Diagnostics Market, Sub-Segmentation Of Colposcopy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Standard Colposcopy
  • Digital Colposcopy
  • Optical Colposcopy
  • 6.7. Global Cervical Cancer Diagnostics Market, Sub-Segmentation Of Biopsy And Endocervical Curettage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Punch Biopsy
  • Endocervical Curettage (ECC)
  • Cone Biopsy
  • Colposcopic Biopsy
  • 6.8. Global Cervical Cancer Diagnostics Market, Sub-Segmentation Of Other Diagnostic Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Visual Inspection With Acetic Acid (VIA)
  • Cervical Cytology Testing
  • Blood Tests
  • Other Specialty Tests

7. Cervical Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Cervical Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Cervical Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cervical Cancer Diagnostics Market

  • 8.1. Asia-Pacific Cervical Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cervical Cancer Diagnostics Market

  • 9.1. China Cervical Cancer Diagnostics Market Overview
  • 9.2. China Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cervical Cancer Diagnostics Market

  • 10.1. India Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cervical Cancer Diagnostics Market

  • 11.1. Japan Cervical Cancer Diagnostics Market Overview
  • 11.2. Japan Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cervical Cancer Diagnostics Market

  • 12.1. Australia Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cervical Cancer Diagnostics Market

  • 13.1. Indonesia Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cervical Cancer Diagnostics Market

  • 14.1. South Korea Cervical Cancer Diagnostics Market Overview
  • 14.2. South Korea Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cervical Cancer Diagnostics Market

  • 15.1. Western Europe Cervical Cancer Diagnostics Market Overview
  • 15.2. Western Europe Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cervical Cancer Diagnostics Market

  • 16.1. UK Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cervical Cancer Diagnostics Market

  • 17.1. Germany Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cervical Cancer Diagnostics Market

  • 18.1. France Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cervical Cancer Diagnostics Market

  • 19.1. Italy Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cervical Cancer Diagnostics Market

  • 20.1. Spain Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cervical Cancer Diagnostics Market

  • 21.1. Eastern Europe Cervical Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cervical Cancer Diagnostics Market

  • 22.1. Russia Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cervical Cancer Diagnostics Market

  • 23.1. North America Cervical Cancer Diagnostics Market Overview
  • 23.2. North America Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cervical Cancer Diagnostics Market

  • 24.1. USA Cervical Cancer Diagnostics Market Overview
  • 24.2. USA Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cervical Cancer Diagnostics Market

  • 25.1. Canada Cervical Cancer Diagnostics Market Overview
  • 25.2. Canada Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cervical Cancer Diagnostics Market

  • 26.1. South America Cervical Cancer Diagnostics Market Overview
  • 26.2. South America Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cervical Cancer Diagnostics Market

  • 27.1. Brazil Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cervical Cancer Diagnostics Market

  • 28.1. Middle East Cervical Cancer Diagnostics Market Overview
  • 28.2. Middle East Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cervical Cancer Diagnostics Market

  • 29.1. Africa Cervical Cancer Diagnostics Market Overview
  • 29.2. Africa Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cervical Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Cervical Cancer Diagnostics Market Competitive Landscape
  • 30.2. Cervical Cancer Diagnostics Market Company Profiles
    • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Becton Dickinson and Company (BD) Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Cervical Cancer Diagnostics Market Other Major And Innovative Companies

  • 31.1. QIAGEN N.V.
  • 31.2. Quest Diagnostics Incorporated
  • 31.3. Siemens Healthineers AG
  • 31.4. Zilico Ltd.
  • 31.5. Guided Therapeutics Inc.
  • 31.6. Thermo Fisher Scientific Inc.
  • 31.7. Carl Zeiss AG
  • 31.8. OncoHealth Corporation
  • 31.9. Arbor Vita Corporation
  • 31.10. Micromedic Technologies Ltd.
  • 31.11. Trovagene Inc.
  • 31.12. Roche Diagnostics
  • 31.13. Nucleix Ltd.
  • 31.14. BGI Genomics Co. Ltd.
  • 31.15. Cepheid

32. Global Cervical Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cervical Cancer Diagnostics Market

34. Recent Developments In The Cervical Cancer Diagnostics Market

35. Cervical Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Cervical Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Cervical Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Cervical Cancer Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer